Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [HEALTH]
11 clusters · 25 sources · 41 days · First seen · Last updated
Advances and challenges in mRNA and immunotherapy trials
Overview
Cancer immunotherapy is evolving through personalized mRNA vaccines and cellular therapies. Recent breakthroughs include a platform generating T-cells from hematopoietic stem cells, which offers a ready-to-use alternative to traditional, costly methods of extracting and modifying a patient’s own cells. This approach has shown promise in targeting lung and ovarian tumors with superior persistence.
In the mRNA sector, Moderna’s personalized vaccine, intismeran, has reached significant milestones. Results from the Phase III INTerpath-001 clinical trial involving 1,137 patients with high-risk melanoma show that combining the vaccine with the immunotherapy drug Keytruda significantly reduces the risk of recurrence or death. Specifically, 82.2% of patients in the combination group remained recurrence-free after a median follow-up of 24.6 months, compared to 70.0% in the group receiving Keytruda alone. The data also indicates a 38% reduction in the risk of cancer spread.
The vaccine is custom-designed for each patient by targeting neoantigens—proteins resulting from specific genetic mutations within an individual's tumor—and involves a regimen of nine doses administered at three-week intervals.
While medical experts, including researchers from MD Anderson Cancer Center, have hailed these results as a “significant breakthrough,” the stock market reaction was mixed. Following the detailed presentation of the data, Moderna shares experienced a significant decline, dropping as much as 25% to approximately $181, despite previous surges based on earlier, less detailed reports.
Other developments include positive early results for a breast cancer vaccine at the Cleveland Clinic and a study in the Netherlands where immunotherapy supplemented traditional methods for colorectal cancer, resulting in no recorded recurrences within five years. Despite this progress, the field faces hurdles, including medical disinformation and the complex clinical challenge of transitioning from infectious disease vaccine success to oncology.
Entities
Moderna · Merck · JAMA · National and Kapodistrian University of Athens · Alexandra Hospital
Timeline
-
[HEALTH] 2 sourcesImmunotherapy advancements show promise in treating colorectal and melanoma cancers
New studies show immunotherapy and personalized mRNA vaccines significantly reduce recurrence and death risks in colorectal cancer and melanoma patients.
-
[TECHNOLOGY] 2 sourcesmRNA cancer vaccine research sees clinical breakthroughs and setbacks
mRNA cancer vaccine research is advancing with Moderna's Phase 3 success and promising ovarian cancer trials, even as BioNTech faces clinical setbacks in its colorectal cancer programs.
-
[HEALTH] 4 sourcesImmunotherapy trials show promise as alternatives to chemotherapy
New clinical trials are testing personalized immunotherapy and mRNA vaccines as potential alternatives or supplements to traditional chemotherapy for breast cancer and melanoma patients.
-
[HEALTH] 2 sourcesmRNA technology advances toward personalized melanoma treatments
mRNA technology is advancing beyond COVID-19 vaccines toward personalized cancer treatments, including successful phase 3 trials for high-risk melanoma vaccines led by Merck and Moderna.
-
[HEALTH] 2 sourcesPersonalized cancer vaccine shows promise in small kidney cancer trial
A small clinical trial shows nine kidney cancer patients have not seen a recurrence after receiving a personalized vaccine designed to train the immune system to target specific tumor neoantigens.
-
[HEALTH] 2 sourcesImmunotherapy and mRNA vaccines advance melanoma treatment
Immunotherapy has extended survival for Stage IV melanoma patients by over a decade. New personalized mRNA vaccines are currently in Phase III trials to prevent cancer relapses.
-
[HEALTH] 2 sourcesCancer vaccine research shows progress in prevention and treatment
New research published in JAMA details advancements in cancer vaccine technology, utilizing identified tumor antigens and improved delivery systems to enhance the immune system's ability to fight cancer.
-
[HEALTH] 4 sourcesCancer vaccine research sees advancements in immunology and technology
New research published in JAMA details advancements in anti-cancer vaccines, driven by the identification of over 2,000 tumor antigens and improved delivery technologies to trigger immune responses.
-
[HEALTH] 2 sourcesmRNA technology shows promise in cancer vaccine development
mRNA technology is showing promise in cancer vaccine development, with recent studies showing significant success in reducing melanoma recurrence through personalized immunotherapy.
-
[HEALTH] 2 sourcesCancer vaccine progress faces threat from disinformation
Medical experts warn that disinformation could hinder the adoption of promising new cancer vaccines, including mRNA-based treatments currently showing success in clinical trials.
-
[HEALTH] 2 sourcesCancer immunotherapy advances with stem cell T-cells and mRNA vaccines
New breakthroughs in cancer treatment include ready-to-use T-cell therapies derived from stem cells and personalized mRNA vaccines designed to prevent melanoma recurrence.
Sources
5min.at · bezirksjournal.at · brasilemfolhas.com.br · disa.org · dn.pt · farmacoecura.it · healthreport.gr · innlifes.com · limassoltoday.com.cy · nasza-holandia.pl · newsable.asianetnews.com · newsbeast.gr · newstalkflorida.com · panorama.it · pozeski.hr · rynekzdrowia.pl · sapo.pt · statnews.com · stiripesurse.ro · theascent.com · thessnews.gr · thestival.gr · truthout.org · zougla.gr · zvornicki.ba
This summary has been updated 10 times: see revision history